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Growth of prostate cancer cells is dependent upon
androgen stimulation of the androgen receptor
(AR). Dihydrotestosterone (DHT), the most potent
androgen, is usually synthesized in the prostate
from testosterone secreted by the testis. Following
chemical or surgical castration, prostate cancers
usually shrink owing to testosterone deprivation.
However, tumors often recur, forming castration-
resistant prostate cancer (CRPC). Here, we show
that CRPC sometimes expresses a gain-of-stability
mutation that leads to a gain-of-function in 3b-hy-
droxysteroid dehydrogenase type 1 (3bHSD1), which
catalyzes the initial rate-limiting step in conversion of
the adrenal-derived steroid dehydroepiandrosterone
to DHT. The mutation (N367T) does not affect cata-
lytic function, but it renders the enzyme resistant to
ubiquitination and degradation, leading to profound
accumulation. Whereas dehydroepiandrosterone
conversion to DHT is usually very limited, expression
of 367T accelerates this conversion and provides the
DHT necessary to activate the AR. We suggest that
3bHSD1 is a valid target for the treatment of CRPC.
INTRODUCTION
The growth of cancerous prostate cells requires stimulation of
the androgen receptor (AR) by androgens, the most potent of
which is dihydrotestosterone (DHT). Advanced prostate cancer1074 Cell 154, 1074–1084, August 29, 2013 ª2013 Elsevier Inc.usually initially regresses with gonadal testosterone (T) depriva-
tion therapy (i.e., medical or surgical castration), but it almost
always eventually progresses as castration-resistant prostate
cancer (CRPC) (Attard et al., 2009; Penning, 2010; Scher and
Sawyers, 2005; Sharifi et al., 2005; Yuan and Balk, 2009). The
CRPC phenotype is driven by a gain of function in the androgen
receptor (AR) that is usually accompanied by intratumoral DHT
concentrations of about 1 nM, an amount sufficient to drive
expression of AR-induced genes, including the TMPRSS2-ETS
fusion oncogene (Geller et al., 1978; Luu-The et al., 2008; Mont-
gomery et al., 2008; Sharifi, 2013; Titus et al., 2005; Tomlins
et al., 2005). The requirement for intratumoral androgen synthe-
sis in driving CRPC progression is most clearly demonstrated
by the survival benefit conferred by abiraterone acetate, a drug
that blocks androgen synthesis by inhibiting 17a-hydroxylase/
17,20-lyase (CYP17A1), and enzalutamide, a potent AR antago-
nist that blocks DHT access to the AR ligand-binding domain
(Barrie et al., 1994; de Bono et al., 2011; Scher et al., 2012;
Tran et al., 2009). Intratumoral synthesis of DHT from precursors
that are secreted from the adrenal gland occurs through a
pathway that circumvents T (Chang et al., 2011). This synthesis
requires three enzymes: 3b-hydroxysteroid dehydrogenase
(3bHSD; encoded by HSD3B), steroid-5a-reductase (SRD5A),
and 17b-hydroxysteroid dehydrogenase (17bHSD) isoenzymes
(see Figure 1A) (Chang et al., 2011; Knudsen and Penning,
2010). Nonetheless, increased DHT synthesis in CRPC has not
yet been ascribed to any mutations in genes encoding com-
ponents of the steroidogenic machinery. 3bHSD oxidizes
3b-hydroxyl to 3-keto and isomerizes D5 to D4 (see Figure 1A),
reactions that together make this step practically irreversible
by an enzyme that is required for all possible pathways that
lead to the synthesis of DHT (Evaul et al., 2010). HSD3B1
encodes for the peripherally expressed isoenzyme (3bHSD1)
and has a germline single-nucleotide polymorphism (SNP) at
position 1245 of HSD3B1, converting A/ C, which exchanges
an asparagine (N) for a threonine (T) at 3bHSD1 amino acid posi-
tion 367.
Here, we show that CRPC sometimes expresses the 367T
form of 3bHSD1 (3bHSD1(367T)), which increases metabolic
flux from dehydroepiandrosterone (DHEA) via the 5a-androsta-
nedione (5a-dione) pathway to DHT by protein resistance to
ubiquitination and degradation rather than increased catalytic
activity. Selection for 3bHSD1(367T) is evident from somatic
mutation in human CRPC tumors, by loss of heterozygosity
(LOH) of the wild-type copy in patients with germline hetero-
zygous inheritance, and from the generation and expression of
the same somatic mutation occurring in a mouse xenograft
model treated with abiraterone acetate.
RESULTS
Cells with 3bHSD1(367T) Have Increased Flux to DHT
Conversion of DHEA by 3bHSD1 toD4-androstenedione (AD) is a
proximal step in peripheral tissues for metabolism from adrenal
precursors to DHT (Lorence et al., 1990; Simard et al., 2005).
Two cell lines derived from patients with CRPC have widely
disparate flux from DHEA to AD (Figure 1A), despite comparable
expression of transcripts encoding both 3bHSD1 and 3bHSD2
(Figure S1A available online). Under the same conditions, LNCaP
cells metabolize >90% of [3H]-DHEA by 3bHSD enzymatic
activity to AD after 48 hr, whereas LAPC4 cells metabolize only
approximately 10% of [3H]-DHEA. In LAPC4, but not in LNCaP,
apparent rate-limiting conversion of DHEA to AD, en route to
DHT via the dominant pathway (DHEA / AD / 5a-dione /
DHT) (Chang et al., 2011), is further evident by limited accumu-
lation of downstream metabolites and absence of DHEA con-
centration-dependent increases in AR-regulated PSA and
TMPRSS2 (Figure 1B). Sequencing the exons of both HSD3B
isoenzymes reveals a single nonsynonymous substitution
(Figure 1C) at position 1245 of HSD3B1, converting A / C,
and exchanges an asparagine (N) for a threonine (T) at 3bHSD1
amino acid position 367 in LNCaP, but not in LAPC4. To further
test the association between HSD3B1 sequence and steroid
metabolism, other human prostate cell lines were investigated.
The presence of wild-type (1245A) and variant (1245C)
HSD3B1 sequences in other prostate cancer and immortalized
prostate cell lines is also concordant with ‘‘slow’’ and ‘‘fast’’
flux from DHEA to AD, respectively (Figure S1B). The kinetic
properties of recombinant 3bHSD1(367N) and 3bHSD1(367T)
proteins, however, do not explain the differences in steroid
metabolism between cells expressing each protein (Figure 1D).
Western blot was performed to determine if the allele encoding
3bHSD1(367T) is associated with a greater amount of protein
in these cells. Both models that encode for 3bHSD1(367T)
have increased 3bHSD1 protein compared with the models
that have wild-type sequence (Figure 1E).
Androgen Deprivation Selects for HSD3B1(1245C)
The HSD3B1(1245C); 3bHSD1(367T) allele occurs as a germline
SNP variant (rs1047303; 22% allele frequency) (Shimodairaet al., 2010) but might also occur as a somatic mutation in pros-
tate cancer. Although germline homozygous HSD3B1(1245C)
inheritance cannot be ruled out, the most likely scenarios
accounting for the sole presence of the HSD3B1(1245C) allele
evident in both LNCaP and VCaP, given the low expected
frequency of homozygous HSD3B1(1245C) inheritance, are
either germline heterozygous inheritance followed by loss of
heterozygosity (LOH) of the wild-type allele or germline homo-
zygous wild-type inheritance followed by somatic mutation
of 1245 A / C. To identify the existence of these possible
mechanisms of HSD3B1(1245C) selection in human tumors,
matching germline and tumor DNA were sequenced from men
with CRPC. Genomic DNA was isolated from CRPC and normal
tissue from patients treated at the University of Texas South-
western Medical Center (UTSW) and from the University of
Washington (UW) rapid autopsy program (Montgomery et al.,
2008). Patient and tumor characteristics are available in Table
S1. Of 40 men with CRPC, the germline of 25, 11, and 4 individ-
uals is homozygous wild-type HSD3B1(1245A), heterozygous
and homozygous variant HSD3B1(1245C), respectively. Three
of 25 (12%) CRPC tumors with homozygous HSD3B1(1245A)
inheritance have acquired the HSD3B1(1245C) allele (Figure 2A).
Expression of HSD3B1(1245C) transcript was confirmed in
the one available fresh-frozen tumor. It is highly likely that the
observation of three identical de novo mutations occurring in
25 patients is due to selection rather than chance alone, with a
high degree of statistical significance (p = 1.47 3 1013), using
the binomial method and assuming a mutation rate of 4 per
1,000,000 base pairs (Greenman et al., 2007). Of 11 CRPC
tumors with heterozygous inheritance, three (27%) have LOH
of the HSD3B1(1245A) allele, resulting in the HSD3B1(1245C)
allele being predominantly detectable (Figure 2B). In these three
tumors, LOH of adjacent heterozygous SNPs further confirms
loss of this region of chromosome 1. In contrast, none of the
11 cases with heterozygous inheritance exhibited LOH of the
HSD3B1(1245C) allele (Figure S2A).
Two tumors (UW9 andUW25) with LOHof theHSD3B1(1245A)
allele had tissue remaining for additional studies. Consistent
with the findings in LNCaP and VCaP that only have the
HSD3B1(1245C) allele, both of these tumors have abundant
detectable 3bHSD1 protein (Figure 2C). In contrast, both
tumors tested with heterozygous expression and homozy-
gous HSD3B1(1245A) expression have little or no detectable
3bHSD1. Messenger RNA (mRNA) quantitation by qRT-PCR
demonstrates that the increased 3bHSD1 protein abundance
occurring specifically in the tumors with LOH is not attributable
to transcript overexpression (Figure S2B). Both tumors with
LOH robustly express AR and PSA, suggesting that flux to
DHT sustained by 3bHSD1 protein functions to elicit AR signaling
(Figure 2C).
Abiraterone inhibits CYP17A1 and weakly inhibits 3bHSD,
further decreasing intratumoral androgen concentrations and ex-
tending survival in CRPC (de Bono et al., 2011; Li et al., 2012);
therefore, conversion to the HSD3B1(1245C) allele encoding
3bHSD1(367T) might permit sustained androgen synthesis
despite lower availability of precursors. To determine if abirater-
one treatment selects for the HSD3B1(1245C) allele, genomic
DNA from LAPC4 xenograft tumors grown in orchiectomizedCell 154, 1074–1084, August 29, 2013 ª2013 Elsevier Inc. 1075
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Figure 1. The 3bHSD1(367T) Protein Encoded byMutantHSD3B1(1245C) Increases Flux fromDHEA to AD, which Is Otherwise Rate-Limiting,
En Route to DHT and Expression of AR-Responsive Genes
(A) Metabolic flux from [3H]-DHEA (100 nM) to AD and downstream to 5a-dione and DHT is robust in LNCaP but limited in LAPC4. The metabolic pathway
and steroid structures are shown, indicating sites of modification by 3bHSD1 in converting DHEA to AD. Steroids were quantitated at the indicated time points by
high-performance liquid chromatography (HPLC).
(B) DHEA induces PSA and TMPRSS2 expression in a concentration-dependent manner in LNCaP, but not in LAPC4. Expression was assessed by qRT-PCR
and normalized to RPLP0 and vehicle control.
(C) A substitution converting A / C at position 1245 in HSD3B1 occurs in LNCaP and VCaP, encoding a change from N / T at amino acid 367 in
3bHSD1.
(legend continued on next page)
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Figure 2. Somatic Selection for HSD3B1
(1245C) Encoding 3bHSD1(367T) Occurs
with Resistance to Androgen Deprivation
(A) Conversion from A/ C in HSD3B1 occurs in
three CRPC tumors from patients with homozy-
gous wild-type inheritance. Sequence of cDNA
clones from a fresh-frozen tumor (UTSW7) con-
firms expression of HSD3B1(1245C) transcript.
(B) Three CRPC tumors from patients with
heterozygous inheritance exhibit LOH of the
wild-type HSD3B1(1245A) allele. Sequencing
informative (heterozygous) adjacent 50 (rs6203)
and 30 (rs34814922 and rs113096733) SNPs
confirms LOH.
(C) 3bHSD1 protein is abundant in tumors with
LOH of the HSD3B1(1245A) allele, but not in
tumors with heterozygous expression or homo-
zygous HSD3B1(1245A) expression. Both tumors
with LOH tested also express AR and PSA (20 mg
protein loaded per lane for each tumor).
(D) Somatic mutation converting A / C in
HSD3B1 occurs in two LAPC4 xenograft tumors
treated with abiraterone acetate (Abi) after orchi-
ectomy and expression of HSD3B1(1245C)
transcript encoding 3bHSD1(367T) is evidenced
by sequencing cDNA clones from these tumors.
Genomic sequence from two representative
control tumors (CTRL#1 and CTRL#2) treated
with orchiectomy alone is shown for com-
parison. All 37 cDNA clones from CTRL#1 and
CTRL#2 have HSD3B1(1245A) transcript encod-
ing 3bHSD1(367N).
See also Figure S2 and Table S1.mice treatedwith abiraterone or vehicle (n =8mice per treatment)
was isolated and sequenced (Li et al., 2012). The 1245C allele is
detectable in 2 of 8 tumors (Abi #1 and Abi #2) in the abiraterone
treatment group and no tumors in the vehicle group (Figure 2D).
To confirm expression of the somatically acquired mutation in
the abiraterone group, complementary DNA (cDNA) clones
were generated and sequenced. The mutant HSD3B1(1245C)
transcript encoding for 3bHSD1(367T) is confirmed in 12 of 21
(57%) cDNA clones sequenced from Abi #1 and 7 of 26 (27%)(D)Wild-type 3bHSD1(367N) and 3bHSD1(367T) have comparable kinetic properties.Michaelis-Menten plot o
3bHSD1(367T) (square) enzyme. The KM for 3bHSD1(367N) and 3bHSD1(367T) protein is 32 and 77 mM, res
(E) Endogenous expression of 3bHSD1(367T) is associated with increased protein quantity. Error bars in (A
performed in triplicate.
See also Figure S1.
Cell 154, 1074–1084,clones fromAbi #2. In contrast, themutant
transcript is not present in any of the 37
cDNA clones obtained from two vehicle-
treated LAPC4 xenograft tumors.
Blocking 3bHSD1(367T) Inhibits
DHT Synthesis, the AR Response,
and CRPC
To determine the role of 3bHSD1(367T)
expression in regulating flux from DHEA
to DHT and AR stimulation, endogenousexpression was silenced in LNCaP using two independent lenti-
viral short hairpin RNAs (shRNAs) (Figure 3A). Blocking 3bHSD1
expression with both shRNAs inhibits flux from DHEA to AD,
resulting in little or no detectable conversion to downstream
5a-dione and DHT (Figure 3B). Silencing expression of mutant
3bHSD1 and blocking flux to DHT impedes the expression of
AR-regulated PSA and TMPRSS2 (Figure 3C), leading to inhi-
bition of cell proliferation in vitro (Figure 3D). In vivo, depletion
of endogenously expressed mutant 3bHSD1 significantlyf DHEAmetabolismwith 3bHSD1(367N) (circle) and
pectively.
), (B), and (D) represent the SD from experiments
August 29, 2013 ª2013 Elsevier Inc. 1077
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Figure 3. Genetic Silencing of 3bHSD1(367T) Impedes Conversion of DHEA to DHT, Induction of PSA and TMPRSS2 Expression, and
CRPC Growth
(A) Stable lentiviral expression of two independent shRNA constructs against HSD3B1 (shHSD3B1 #1 and shHSD3B1 #2) silences 3bHSD1 protein expression in
LNCaP. The 3bHSD1 protein was quantitated and normalized to cells expressing nonsilencing lentiviral vector (shCTRL) and b-actin.
(B) Silencing 3bHSD1(367T) blocks flux from [3H]-DHEA (100 nM) to AD as well as further downstream conversion to 5a-dione and DHT. Cells were treated with
[3H]-DHEA in triplicate, and steroids were quantitated with HPLC at the designated time points.
(C) Inhibition of AR-regulated genes. Cells were treated with the indicated concentration of DHEA for 24 hr, and gene expression was assessed by qRT-PCR and
normalized to shCTRL-infected cells treated with vehicle and the RPLP0 housekeeping gene.
(D) Silencing 3bHSD1(367T) inhibits in vitro growth. Cells were grown in the presence of 20 nM DHEA or vehicle, and growth for each cell line was normalized to
vehicle for each designated day.
(legend continued on next page)
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Figure 4. Resistance to Ubiquitination and
Proteosome-Mediated Degradation Occurs
with 3bHSD1(367T), Resulting in Prolonged
Protein Half-Life
(A) 3bHSD1(367T) persists after inhibition of pro-
tein translation. LAPC4 cells were transiently
transfected with constructs encoding for wild-type
(N-HA) and (T-HA) protein and treated with cyclo-
heximide (CHX) for the designated incubation
times. Western blot with anti-HA antibody was
performed, and the signal was quantitated and
normalized to time zero and b-actin.
(B) Treatment with MG132 (10 mM; 8 hr) reverses
3bHSD1(367N) protein loss in LAPC4 and results
in no 3bHSD1(367T) protein increase in LNCaP.
(C) Proteosome inhibition withMG132 (10 mM; 8 hr)
results in an increase in polyubiquitinated
3bHSD1(367N) protein in LAPC4 as evidenced by
immunoprecipitation with an anti-ubiquitin anti-
body. H.C., heavy chain.
(D) Loss of 3bHSD1(367T) vulnerability to pro-
teosome-mediated degradation is explained by
diminished susceptibility to ubiquitination. His-
ubiquitin (His-ubi) was expressed with wild-type
(N-HA) or (T-HA) protein in 293 cells, followed by
pull-down with Ni-agarose beads and anti-HA
immunoblot.
See also Figure S3.hinders CRPC growth in surgically orchiectomized mice (Fig-
ure 3E). CRPC tumors that eventually develop from cell lines
initially expressing lentiviral shRNA knockdown constructs re-
gain 3bHSD1 protein, probably from selection for cells that
have lost the shRNA construct (Figure 3F).
3bHSD1(367T) Is Resistant to Ubiquitination
and Degradation
Endogenous expression of 3bHSD1(367T) appears to engender
increased protein abundance compared to expression of
3bHSD1(367N) (Figure 1E). To determine if the underlying mech-
anism is due to an alteration in protein degradation, wild-type
(HSD3B1(N)-HA) and (HSD3B1(T)-HA) constructs were gener-
ated and transiently expressed, and protein levels were
compared following inhibition of translation with cycloheximide
(CHX) treatment. The 367 N / T mutation substantially in-
creases protein half-life from 2.1 to 27 hr (Figure 4A). Similar
experiments with an alternative prostate cancer cell line (Fig-
ure S3A) and with stable expression of lentiviral constructs
confirm the longer half-life of 3bHSD1(367T) (Figure S3B). To
determine whether increased degradation of wild-type protein
is reversible with proteasome inhibition, cells were treated
with MG132. Pharmacologic proteasome inhibition increases
endogenous wild-type 3bHSD1(367N) in LAPC4 but does not(E) 3bHSD1(367T) depletion blocks CRPC growth in LNCaP xenografts. Mice u
when xenograft tumors reached a threshold volume of 100 mm3. Fifteen mice w
shHSD3B1 #2 groups, respectively, achieved a tumor volume of 100 mm3 in eugo
The number of days from orchiectomy to tumor volumeR600 mm3 is shown. In th
and 0.003, respectively, using a log rank test.
(F) 3bHSD1(367T) protein is regained in CRPC tumors that grow from LNCaP exp
were performed on protein from the indicated LNCaP CRPC tumors. Error barsincrease 3bHSD1(367T) in LNCaP (Figure 4B), and polyubiquiti-
nated endogenous 3bHSD1(367N) accumulates with MG132
treatment in LAPC4 (Figure 4C). In contrast, polyubiquitinated
endogenous 3bHSD1(367T) is not increased in LNCaP with
MG132 treatment (Figure S3C). A direct comparison of ubiquiti-
nation between HA-tagged wild-type and mutant protein by
Ni-agarose pull-down demonstrates that 3bHSD1(367T) is
resistant to polyubiquitination (Figure 4D), explaining decreased
vulnerability to proteasome-mediated degradation and longer
protein half-life.
AMFR Binds 3bHSD1(367N) and Is Required
for Ubiquitination
We employed mass spectrometry to determine the lysine
residue(s) ubiquitinated on 3bHSD1(367N). Ubiquitination is
detectable on both K70 (Figure 5A) and K352 (Figure 5B) of
3bHSD1(367N). The effects of K352R and K70R single mutations
and a double mutation on ubiquitination were assessed by
Ni-agarose pull-down (Figure 5C). K352 appears to be a more
critical site of ubiquitination than does K70, and mutation of
both sites decreases ubiquitination greater than does either
mutation alone.
Autocrinemobility factor receptor (AMFR, also known as gp78)
is a membrane-anchored ubiquitin ligase that functions throughnderwent surgical orchiectomy and DHEA pellet implantation concomitantly
ere initiated in each cohort, 7, 8, and 10 mice in shCTRL, shHSD3B1 #1, and
nadal mice, underwent orchiectomy, and were included in the CRPC analysis.
e comparisons of shCTRL versus shHSD3B1 #1 and shHSD3B1 #2, p = 0.002
ressing shHSD3B1 #1 and shHSD3B1 #2. Immunoblot for 3bHSD1 and b-actin
in (B), (C), and (D) represent the SD for experiments performed in triplicate.
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Figure 5. The ER-Associated Degradation
Pathway and AFMR Regulate 3bHSD1
Ubiquitination and Degradation
(A and B) K70 and K352 ubiquitination on 3bHSD1
(367N) is detectable by mass spectrometry.
(C) K70, 352R mutant 3bHSD1(367N) is resistant
to ubiquitination. K70R and K352R single- and
double-mutant forms of N-HA were expressed
with His-ubi in 293 cells, followed by pull-down
with Ni-agarose beads and anti-HA immunoblot.
(D) Treatment with the ERAD inhibitor Eeyarestatin
I (EerI, 10 mM) increases endogenous 3bHSD1
protein in LAPC4.
(E) AMFR preferentially physically associates with
wild-type protein (N-HA). Proteins were expressed
in 293 cells and immunoprecipitated with anti-HA
antibody, followed by immunoblot for AMFR. H.C.,
heavy chain.
(F)Silencing theubiquitinE3-ligaseAMFR increases
3bHSD1 protein detected in LAPC4 cells. In con-
trast, genetically silencing the ubiquitin E3-ligase
SKP2 has no detectable effect on 3bHSD1.the endoplasmic reticulum-associated protein degradation
(ERAD) pathway (Song et al., 2005). Eeyarestatin I (EerI) is
a small molecule that inhibits protein degradation through
the ERAD pathway (Wang et al., 2008, 2009). Endogenous
3bHSD1(367N) protein increases in LAPC4 cells with EerI treat-
ment, suggesting that the ERAD pathway is required for
3bHSD1(367N) degradation (Figure 5D). Stable isotope labeling
by amino acids in cell culture (SILAC) coupled with high-resolu-
tion mass spectrometry was employed to identify candidate
ubiquitin ligases in an unbiased manner that preferentially asso-
ciate with 3bHSD1(367N) (Ong et al., 2002). In this experiment,
cells expressing 3bHSD1(367T)-HA and 3bHSD1(367N)-HA
weregrown in light andheavymedia, respectively. AMFRwasde-
tected with a normalized protein ratio of 1.67 (derived from pep-
tide ratios varying%17%) in a mixture of 3bHSD1(367N)-HA and
3bHSD1(367T)-HA immunoprecipitations mixed in a 1:1 ratio,
indicating preferential physical association with 3bHSD1(367N)
protein. Immunoprecipitation of 3bHSD1(367N)-HA and
3bHSD1(367T)-HA, followed by AMFR immunoblot, confirms a1080 Cell 154, 1074–1084, August 29, 2013 ª2013 Elsevier Inc.preferential physical association of
AMFR with 3bHSD1(367N) protein (Fig-
ure 5E). To assess the functional conse-
quence of this interaction, AMFR was
silenced using siRNA (Figure 5F). AMFR
knockdown increases the abundance of
3bHSD1 protein, demonstrating the
requirement of AMFR for 3bHSD1 degra-
dation through the ERAD pathway. In
contrast, silencing the alternative ubiqui-
tin ligase SKP2 by siRNA had no detect-
able effect on 3bHSD1.
3bHSD1(367T) Increases DHT
Synthesis
To determine if resistance to protein
ubiquitination and degradation ascribedto 3bHSD1(367T) confers increased synthesis of DHT from pre-
cursor steroids, we expressed constructs that encode for
3bHSD1(367N), 3bHSD1(367T), or vector alone in LAPC4 cells
and assessed metabolic flux from [3H]-DHEA to downstream
steroids. LAPC4 cells transiently transfected with the construct
encoding for 3bHSD1(367T) exhibit increased flux from DHEA
/ AD/ 5a-dione/ DHT (Figure 6A). Equivalent expression
of both transcripts was confirmed by qRT-PCR (Figure 6B).
Stable lentiviral expression of 3bHSD1(367T) similarly confers
increased flux from DHEA / AD / 5a-dione / DHT (Fig-
ure 6C), with transcript expression comparable to wild-type
transcript expression (Figure 6D). Finally, we determined that
the 3bHSD1(367T) phenotype that accelerates flux from
DHEA to DHT amplifies the response of androgen-regulated
gene expression (Figure 6E) and hastens the time to the devel-
opment of CRPC xenograft tumors (Figure 6F) in orchiectom-
ized mice supplemented with DHEA to mimic human adrenal
physiology. 3bHSD1(367T) tumors express higher levels of
PSA transcript compared to 3bHSD1(367N) tumors, suggesting
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Figure 6. 3bHSD1(367T) Increases Metabolic Flux from DHEA to DHT and Elicits CRPC
(A) Transient expression of 3bHSD1(367T) (T, blue bars) leads to increased conversion fromDHEA to AD and downstream steroids comparedwith 3bHSD1(367N)
(N, red bars). LAPC4 cells were transfected with the indicated plasmid, treated with CHX, and cultured with [3H]-DHEA (100 nM); steroids were extracted and
measured by HPLC at the designated time points (p value = 0.023 for the difference in DHT synthesis by the N and T forms using Student’s t test).
(B) Transient transfection results in equivalent expression of both transcripts by qRT-PCR.
(C) Stable expression demonstrates increased activity of 3bHSD1(367T). Lentiviral constructs expressing luciferase (L), wild-type (N), or (T) were stably expressed
(without CHX treatment), and flux from [3H]-DHEA to DHTwas assessed, as described previously (p value = 0.015 for the difference in DHT synthesis by the N and
T forms using Student’s t test).
(D) Expression of both enzyme transcripts by qRT-PCR is comparable.
(E) Increased flux from DHEA to DHT with stable expression of 3bHSD1(367T) leads to amplified expression of PSA in LAPC4. Cells stably expressing the
designated constructs were treated with the indicated steroids for 48 hr. PSA expression induced by the DHT-positive control is equivalent among the three cell
populations. For (B), (D), and (E), expression is normalized to RPLP0 and vector, luciferase, or vehicle controls. Error bars represent the SD for experiments
performed in triplicate.
(F) Development of CRPC occursmore rapidly in LAPC4 xenografts stably expressing 3bHSD1(367T) as comparedwith 3bHSD1(367N). Time from subcutaneous
injection of cells in each flank to tumor size = 50 mm3 is shown for each tumor that developed in a mouse flank (n = 40 mouse flanks in each group). p = 0.017 for
the comparison using a log rank test.
(G) PSA expression is higher in CRPC tumors expressing 3bHSD1(367T) compared with 3bHSD1(367N) (p value = 0.015 using Student’s t test). Expression is
normalized to RPLP0. Bars represent the upper and lower quartiles of individual tumor values.the presence of higher sustained DHT concentrations gener-
ated in 3bHSD1(367T) tumors (Figure 6G). Together, these find-
ings support a mechanism that favors genetic selection for the
allele encoding 3bHSD1(367T) in the setting of androgen
depletion.
DISCUSSION
Amajormechanism of resistance to frontline gonadal T depletion
(or castration) therapy is an acquired metabolic capability, which
allows CRPC tumors to sustain sufficient DHT concentrations
for AR stimulation and tumor progression. This study identifiesa gain-of-function mutation in the steroidogenic machinery that
increases flux to DHT. Notably, whether CRPC utilizes the
major adrenal pathway, or possibly de novo steroidogenesis
from cholesterol, 3b-hydroxyl oxidation to 3-keto and D5/4
isomerization occurring through 3bHSD enzymatic activity is
required for all pathways culminating in T and/or DHT synthesis
(Evaul et al., 2010). Adrenal DHEA and DHEA-sulfate are
typically present in abundant concentrations in human serum.
In the context of intratumoral 3bHSD1(367N) expression, the
clinical response to gonadal T depletion probably occurs in
part due to the limited contribution of adrenal precursors to
intratumoral DHT. Augmented 3bHSD activity occurringCell 154, 1074–1084, August 29, 2013 ª2013 Elsevier Inc. 1081
through increased protein abundance with 3bHSD1(367T)
would therefore serve to open the floodgates on a proximal
and otherwise rate-limiting step for the synthesis of DHT, result-
ing in the development of CRPC. Notably, in the setting of
heterozygous inheritance, 3bHSD1 protein expression is
markedly higher in tumors that have lost the wild-type
HSD3B1(1245A) allele compared to tumors that retain the wild-
type sequence (Figure 2C). This finding might occur because
expression and colocalization of the wild-type 3bHSD1(367N)
protein reinstates mutant 3bHSD1(367T) ubiquitination and
subsequent degradation via dimerization or oligomerization.
Nonetheless, engineered 3bHSD1(367T) expression engenders
increased flux to DHT and development of CRPC despite
endogenous 3bHSD1(367N) expression (Figure 6). Therefore,
the transition from sole 3bHSD1(367N) expression to mixed
expression to dominant 3bHSD1(367T) expression probably
represents a stepwise selection for an increased capacity for
DHT synthesis.
The population frequency of the HSD3B1(1245C) allele is
approximately 22% but appears to vary widely by ethnicity
(http://genome.ucsc.edu/). Other studies suggest that the
HSD3B1(1245C) allele may raise aldosterone levels and increase
the risk of essential hypertension (Shimodaira et al., 2010). This
is probably attributable to increased 3bHSD enzyme activity,
which is required for aldosterone synthesis, although aldoste-
rone is generally thought to require 3bHSD2. Interestingly, this
phenotype appears to be more severe with homozygous
HSD3B1(1245C). The observation of extremely high aldosterone
with homozygous HSD3B1(1245C) is consistent with higher
enzymatic activity and stepwise selection for sole 3bHSD1(367T)
expression that occurs in CRPC.HSD3B1(1245C) has no consis-
tent effect on risk of localized prostate cancer (Chang et al.,
2002; Cunningham et al., 2007; Thomas et al., 2008).
Although abiraterone potently inhibits androgen synthesis,
clinical studies of urinary androgen metabolites in patients with
CRPC treated with this drug have demonstrated that the block
is incomplete and that the synthesis of residual androgen pre-
cursors persists (Attard et al., 2012). This finding raises the
possibility that tumor mechanisms that augment androgen syn-
thesis from limited precursor steroids by increasing flux to DHT
might contribute to abiraterone resistance (Chang and Sharifi,
2012). Our data demonstrating the selection and expression of
3bHSD1(367T) in a xenograft model of abiraterone resistance
suggest a genetic mechanism for clinical resistance to abirater-
one and that pharmacologic inhibition of 3bHSD1 might be a
viable therapeutic strategy to overcome this resistance against
tumors expressing the mutant enzyme. Despite the potent
activity of the AR antagonist enzalutamide, its affinity for the
ligand-binding domain of AR is lower than the affinity of DHT
(Tran et al., 2009). Increased metabolic flux from steroid pre-
cursors to DHT by 3bHSD1(367T) may therefore conceivably
tip the scales in the favor of DHT and lead to enzalutamide
resistance as well. The contribution of 3bHSD1(367T) in clinical
resistance to abiraterone and enzalutamide, however, remain
to be determined.
The past decade has brought to the fore the development of
molecularly targeted therapies that are matched to specific
disease-driving enzyme mutations present in a given patient.1082 Cell 154, 1074–1084, August 29, 2013 ª2013 Elsevier Inc.These advances come mainly in the form of tyrosine kinase
inhibitors that target gain-of-function mutations in these sig-
naling enzymes. These include the examples of EGF receptor
inhibitors matched with tumors harboring mutant EGF receptor
in non-small-cell lung cancer and BRAF inhibitors for melanomas
that are driven by BRAF mutations (Chapman et al., 2011; Ko-
bayashi et al., 2005; Lynch et al., 2004). In contrast, no examples
of drug targeting based on enzyme mutations exist in the stan-
dard of care for metastatic CRPC. Although our demonstration
is in a gain of function in a metabolic enzyme, rather than a
signaling enzyme, we believe the underlying principle is the
same, and our findings expose the opportunity for matching
a mutant disease-driving enzyme biomarker with its cognate
pharmacologic inhibitor.
EXPERIMENTAL PROCEDURES
Steroid Metabolism Experiments
Steroid metabolism experiments were performed 12 hr after seeding cells by
treatment with 1 ml serum-free medium containing [3H]-labeled DHEA
(100 nM, 300,000–600,000 cpm; PerkinElmer). Aliquots of medium were
collected for up to 48 hr and treated with b-glucuronidase (1,000 units;
Sigma-Aldrich) at 65C for 4 hr. Deconjugated steroids were extracted, evap-
orated under nitrogen stream, dissolved in 50% methanol, and injected on a
Breeze 1525 system equipped with model 717 plus autoinjector (Waters),
and steroid metabolites were separated on a Luna 150 3 3 mm, 3.0 mM
C18 reverse-phase column (Phenomenex). The column effluent was mixed
with Liquiscint scintillation cocktail (National Diagnostics) and analyzed by
a b-RAM model 3 in-line radioactivity detector (IN/US Systems). Steroid
metabolism experiments with transient enzyme expression were performed
with pCMV5-HSD3B1 (367N and 367T) constructs 24 hr after transfection
and 12 hr after treatment with 25 mM cycloheximide (CHX). Steroid
metabolism experiments with stable enzyme expression were performed
after lentiviral infection with pLVX-Tight-Puro vector. Human tissues were
obtained using Institutional Review Board-approved protocols at UT
Southwestern and the University of Washington rapid autopsy program.
Lentiviral constructs were made from miR30-styled shRNA sequences and
cloned into the pGIPZ vector, and infected cells expressing the constructs
were selected with 2 mg/ml puromycin. Gene expression was performed by
qRT-PCR using the iTaq SYBR Green Supermix with the ROX kit (Bio-Rad)
in an ABI-7500 Real-Time PCR machine (Applied Biosystems). Protein half-
life was determined after transient transfection with pCMX-HSD3B1-HA
(367N and 367T) plasmids, followed in 24 hr with 25 mM CHX in serum-
free medium containing 100 nM DHEA. Cells stably expressing HA-tagged
HSD3B1 (367N and 367T) in pLVX-Tight-Puro were used to determine pro-
tein half-life 24 hr after induction of protein expression with 2 ng/ml doxycy-
cline and treatment with CHX.
For details on all other experiments, including cell line and human tissue
analyses, xenograft studies, gene expression studies, mass spectrometry,
and other biochemical experiments, please refer to the Extended Experimental
Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures,
three figures, and one table and can be found with this article online at
http://dx.doi.org/10.1016/j.cell.2013.07.029.
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